
JPXHealthcareMedical - Diagnostics & Research
Latest quote
¥3,555
+¥10.00 · +0.28%
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
Latest quote
¥3,555
+¥10.00 · +0.28%
Regular session · JST · Market data may be delayed.
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
Day range
Current ¥3,555
52-week range
Current ¥3,555
Regular session · JST · Market data may be delayed.
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
Day range
Current ¥3,555
52-week range
Current ¥3,555
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 150.26B JPY | 143.19B JPY | 137.96B JPY | 159.46B JPY | 186.07B JPY |
| Cost of goods sold | 101.57B JPY | 97.33B JPY | 92.34B JPY | 98.02B JPY | 99.12B JPY |
| Gross profit | 48.69B JPY | 45.86B JPY | 45.63B JPY | 61.45B JPY | 86.95B JPY |
| Research and development | — | 260M JPY | 275M JPY | 271M JPY | 302M JPY |
| Selling, general, and administrative | 38.27B JPY | 36.24B JPY | 36.19B JPY | 37.24B JPY | 37.76B JPY |
| Operating expenses | 38.27B JPY | 36.5B JPY | 36.46B JPY | 37.51B JPY | 38.06B JPY |
| Interest income | 106M JPY | — | — | — | — |
| Interest expense | 119M JPY | 118M JPY | 104M JPY | 40M JPY | 36M JPY |
| Depreciation and amortization | 9.12B JPY | 7.72B JPY | 6.79B JPY | 6.35B JPY | 5.89B JPY |
| Operating income | 10.42B JPY | 9.37B JPY | 9.17B JPY | 23.94B JPY | 48.89B JPY |
| Net income | 7.75B JPY | 6.26B JPY | 6.04B JPY | 15.58B JPY | 33.74B JPY |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
¥130
2025 complete year+52.9% since 2021
2026 partial: ¥65.00
¥85.00
2,021
¥125
2,022
¥100
2,023
¥90.00
2,024
¥130
2,025
¥65.00
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Sep 29, 2026 | ¥62.50Semi-Annual | Sep 30, 2026 | Sep 29, 2026 |
DividendUpcoming | Mar 30, 2027 | ¥62.50Semi-Annual | Mar 31, 2027 | Mar 30, 2027 |
Dividend | Mar 30, 2026 | ¥65.00Semi-Annual | Mar 31, 2026 | Jun 29, 2026 |
Dividend | Sep 29, 2025 | ¥60.00Annual | Sep 30, 2025 | Dec 2, 2025 |
Dividend | Mar 28, 2025 | ¥70.00Special | Mar 31, 2025 | Jun 30, 2025 |
Dividend | Sep 27, 2024 | ¥50.00Semi-Annual | Sep 30, 2024 | Dec 3, 2024 |
Ex-dividend Sep 29, 2026
¥62.50
Semi-Annual
Record Sep 30, 2026 · Payment Sep 29, 2026
Ex-dividend Mar 30, 2027
¥62.50
Semi-Annual
Record Mar 31, 2027 · Payment Mar 30, 2027
Ex-dividend Mar 30, 2026
¥65.00
Semi-Annual
Record Mar 31, 2026 · Payment Jun 29, 2026
Ex-dividend Sep 29, 2025
¥60.00
Annual
Record Sep 30, 2025 · Payment Dec 2, 2025
Ex-dividend Mar 28, 2025
¥70.00
Special
Record Mar 31, 2025 · Payment Jun 30, 2025
Ex-dividend Sep 27, 2024
¥50.00
Semi-Annual
Record Sep 30, 2024 · Payment Dec 3, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T256.66M0.01%2.91T JPY0.05%¥413.5-0.48%
Vanguard Total International Stock ETFVXUS6.81M0.00%646.2B USD0.05%$87.14+1.00%
Avantis International Small Cap Value ETFAVDV5.1M0.02%20.6B USD0.36%$111.61+0.72%
Vanguard FTSE Developed Markets ETFVEA4.39M0.00%315B USD0.03%$72.69+1.07%
iShares Core MSCI EAFE ETFIEFA3.04M0.00%193.07B USD0.07%$99.50+1.00%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS1.67M0.01%13.6B USD0.06%$158.56+0.72%
iShares MSCI EAFE Small-Cap ETFSCZ1.5M0.01%12.89B USD0.40%$86.09+0.87%
iShares Core MSCI Total International Stock ETFIXUS1.36M0.00%59.9B USD0.07%$97.22+0.98%
iShares Core TOPIX ETF1475.T
Vanguard Total International Stock ETFVXUS
Avantis International Small Cap Value ETFAVDV
Vanguard FTSE Developed Markets ETFVEA
iShares Core MSCI EAFE ETFIEFA
Vanguard FTSE All-World ex-US Small-Cap ETFVSS
iShares MSCI EAFE Small-Cap ETFSCZ
iShares Core MSCI Total International Stock ETFIXUSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.